Table 2.
Univariable cox regression analysis of clinical factors potentially associated with overall survival (OS) and progression free survival (PFS)
| OS | PFS | |||
|---|---|---|---|---|
| Univariable HR (95 % CI) | p | Univariable HR (95 % CI) | p | |
| Age, years | ||||
| >60 vs. S 60 | 1.25 (0,70-2,23) | 0.44 | 1.10 (0,65-1,85) | 0.72 |
| Sex | ||||
| Female vs. male | 1.19 0.66-2.13) | 0.57 | 1.00 (0.59-1.69) | 0.99 |
| KPS | ||||
| 90 % vs. 70–80% | 0.68 (0.37-1.24) | 0.21 | 0.51 (0.29-0.89) | 0.018 |
| Weight loss | ||||
| S 5 % vs. > 5 % | 0.78 (0.31-1.99) | 0.60 | 1.18 (0.53-2.63) | 0.69 |
| M1-stage - time of occurence | ||||
| Metachronous vs. synchronous | 1.26 (0.71-2.24) | 0.43 | 1.46 (0.87-2.48) | 0.15 |
| Histology | ||||
| Squamous vs.Adeno. | 0.64 (0.28-1.46) | 0.29 | 0.75 (0.37-1.50) | 0.42 |
| T -Stagea | ||||
| T3/T4 vs. T1/T2 | 0.79 (0.41-1.52) | 0.29 | 1.02 (0.59-1.79) | 0.94 |
| N-Stagea | ||||
| N2/N3 vs.N0/N1 | 1.27 (0.71-2.25) | 0.43 | 1.26 (0.74-2.15) | 0.40 |
| Thoracic UICC stage | ||||
| II vs. I | 2.28 (0.87-5.96) | 0.09 | 3.80 (1.36-10.69) | 0.011 |
| III vs. I/II | 0.85 (0.48-1.51) | 0.59 | 0.84 (0.49-1.43) | 0.53 |
| Localization of metastases | ||||
| Other vs. Brain | 0.80 (0.43-1.51) | 0.50 | 0.48 (0.26-0.91) | 0.024 |
| No. of metastases | ||||
| > 2 vs. 1 | 1.10 (0.56-2.17) | 0.79 | 1.26 (0.71-2.26) | 0.43 |
| No. of involved organs | ||||
| > 2 vs. 1 | 1.03 (0.32-3.33) | 0.96 | 2.90 (1.30-6.46) | 0.009 |
| T reatment of primary tumor | ||||
| Without vs. with Surgery | 1.58 (0.74-3.40) | 0.24 | 1.07 (0.58-1.96) | 0.84 |
| T reatment of oligometastases | ||||
| SRS/hSRT/SBRT vs. Surgery | 1.00 (0.36-2.84) | 0.99 | 0.75 (0.29-1.95) | 0.55 |
| FDG-PET based staging | ||||
| PET vs. no PET | 1.00 (0.54-1.84) | 1.00 | 0.84 (0.48-1.47) | 0.54 |
| Additional chemotherapy | ||||
| CT vs. no CT | 0.69 (0.39-1.23) | 0.21 | 0.84 (0.49-1.44) | 0.52 |
SD standard deviation, RT radiotherapy, CT chemotherapy, RCT radiochemotherapy, SBRT stereotactic body radiotherapy, SRS stereotactic radiosurgery, hSRT hypofractionated stereotactic radiosurgery, cf-RT conventionally fractionated radiotherapy, KPS Karnofsky Performance Score
arefers to initial staging also for patients with metachronous metastases